Pistoia Pharma-in-a box: A vision for virtualized pharma in 2020

958 views

Published on

A brief talk given at the Pistoia Alliance Conference Boston April 12th, 2011

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
958
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
12
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Pistoia Pharma-in-a box: A vision for virtualized pharma in 2020

  1. 1. Life Science Collaboration & Virtualization: A Perspective Sean Ekins, Ph.D., D.Sc. Collaborations Director, Collaborative Drug Discovery, Inc., Burlingame CA. [email_address] www.collaborativedrug.com
  2. 2. Major collaborative grants in EU: Framework, IMI …NIH moving in same direction Cross continent collaboration CROs in China, India etc – Pharma’s in US / Europe More industry – academia collaboration ‘not invented here’ a thing of the past More effort to go after rare and neglected diseases -Globalization and connectivity of scientists will be key – Current pace of change in pharma may not be enough. Need to rethink how we use all technologies & resources… 2011
  3. 3. <ul><li>1. Spend less on data generation, descriptors and algorithms – use more open source – use models to help refine testing, external collaborators test your drugs </li></ul><ul><li>2. Selectively share data & models with collaborators and control access </li></ul><ul><li>3. Have someone else host the models / predictions </li></ul><ul><li>4. Predicting properties without the need to know the structures </li></ul>Models Inside company Collaborators Commercial Descriptors Algorithms In house data generation Near Future Data Databases, servers
  4. 4. Could all pharmas share their data as models with each other?
  5. 5. Gupta RR, et al., Drug Metab Dispos, 38: 2083-2090, 2010
  6. 6. Merck KGaA Pfizer Merck GSK Novartis Lilly BMS Could combining models give greater coverage of ADME/ Tox chemistry space and improve predictions? Lundbeck Allergan Bayer AZ Roche BI Merk KGaA
  7. 7. Williams et al., in Press, Arnold and Ekins, PharmacoEconomics 28: 1-5, 2010 Near Future
  8. 8. All pharmas have assets on shelf that reached clinic “ Off the Shelf R&D” Get the crowd to help in repurposing / repositioning these assets How can software help? - Create communities to test - Provide informatics tools that are accessible to the crowd - enlarge user base - Data storage on cloud – integration with public data - Crowd becomes virtual pharma CROs and the “customer” for enabling services Near Future
  9. 9. Near Future Connect to all tools / algorithms for enabling searching Suggest hits for hypothesis testing and translate to clinic Key databases of structures and bioactivity data e.g. Knowledge Globally approved drugs database + Off the shelf molecules Ekins S, Williams AJ, Krasowski MD and Freundlich JS, Drug Disc Today, In press 2011 Pistoia members
  10. 10. 2020 Could our Pharma R&D look like this Massive collaboration networks Crowdsourcing will have a major role in R&D Ekins & Williams, Pharm Res, 27: 393-395, 2010.
  11. 11. Need for more “novel” informatics technologies development Ekins et al, Pharm Res, 27: 2035-2039, 2010. Williams et al., Drug Discovery World, Winter 2009
  12. 12. How to do it better? What can we do with software to facilitate it ? The future is more collaborative We have tools but need integration Find improved secure ways to share structural information without revealing structure Alert people to what others are doing to prevent repetition and foster collaboration Use software and computers/ devices in new ways
  13. 13. What does the Pistoia Alliance mean for CDD? Standards Integration Avoid repetition Develop software that all pharma needs Interaction with industry peers, customers, competitors, collaborators The foundation that holds it all together Help the industry to discover drugs more efficiently and reduce costs Help vendors to find role for their products as pharma reorganizes

×